# Biotech Tracker

> Free biotech catalyst calendar with FDA decisions, trial results, source-linked public activity, and personal watchlists. Data comes from FDA.gov, ClinicalTrials.gov, SEC EDGAR and company press releases; quotes are linked externally on Yahoo Finance. Not investment advice.

All pages are server-rendered HTML; machine-readable JSON, Atom and ICS are linked below. Dates are shown at the precision the source gives ("Q3 2026" is a window, not a day). "PDUFA" = the FDA's target action date on a drug application. Generated 2026-10-27T12:56 UTC.

## Data
- [Upcoming catalysts (JSON)](https://app.biotechtracker.dev/api/events): every event in a date window; params from, to, types, tickers, withReactions=1, ended=1
- [Upcoming catalysts (Atom)](https://app.biotechtracker.dev/feed.xml): the next 90 days as a feed
- [Upcoming catalysts (ICS)](https://app.biotechtracker.dev/feeds/upcoming.ics): dated events as a subscribable calendar
- [Companies (JSON)](https://app.biotechtracker.dev/api/companies): tracked companies with last close, moves and next catalyst
- [Companies index](https://app.biotechtracker.dev/companies): one page per ticker with catalysts, source links, pipeline, and a Yahoo Finance link

## Reference
- [Methodology](https://app.biotechtracker.dev/methodology): event types, sources, date precision, public disclosure coverage
- [Glossary](https://app.biotechtracker.dev/glossary): PDUFA, AdComm, CRL, NDA/BLA, topline
- [Developers](https://app.biotechtracker.dev/developers): the free API, rate limits, feeds
- [Calendar](https://app.biotechtracker.dev/calendar) and [catalyst list](https://app.biotechtracker.dev/catalysts)

## Upcoming catalysts (next 30 days)
- [2026 · AMGN · other: Three MariTide Phase 3 studies in type 2 diabetes to start in 2026](https://app.biotechtracker.dev/events/amgn-other-2026-06-30-three-maritide-phase-3-studies-in-type-2-diabetes-to-start-5019a4de733bef38)
- [2026 · ARGX · other: Adimanebart (ARGX-119) registrational study start in congenital myasthenic syndromes](https://app.biotechtracker.dev/events/argx-other-2026-06-30-adimanebart-argx-119-registrational-study-start-in-congeni-0a23915a2425b773)
- [2026 · ARGX · other: ARGX-121 (anti-IgA) Phase 2 start in IgA nephropathy](https://app.biotechtracker.dev/events/argx-other-2026-06-30-argx-121-anti-iga-phase-2-start-in-iga-nephropathy-3abbc8de6ab7c36d)
- [2026 · ARGX · other: ARGX-118 and ARGX-125 to enter Phase 1 in 2026](https://app.biotechtracker.dev/events/argx-other-2026-06-30-argx-118-and-argx-125-to-enter-phase-1-in-2026-181ddbbf5e2728dd)
- [2026 · BNTX · readout: Multiple pumitamig combination data readouts expected in 2026](https://app.biotechtracker.dev/events/bntx-readout-2026-06-30-multiple-pumitamig-combination-data-readouts-expected-in-496fbd2c565bcbdf)
- [2026 · CRSP · readout: Lp(a) program (CTX320/CTX321) update expected in 2026](https://app.biotechtracker.dev/events/crsp-readout-2026-06-30-lp-a-program-ctx320-ctx321-update-expected-in-2026-79335def0430373b)
- [2026 · MRNA · approval: mRNA-1010 (mFLUSIVA) ex-US approvals (EU/Canada/Australia) expected to begin](https://app.biotechtracker.dev/events/mrna-approval-2026-06-30-mrna-1010-mflusiva-ex-us-approvals-eu-canada-australia-c498238271676576)
- [2026 · PFE · readout: Mevrometostat MEVPRO-1 Ph3 mCRPC readout](https://app.biotechtracker.dev/events/pfe-readout-2026-06-30-mevrometostat-mevpro-1-ph3-mcrpc-readout-ea98728fbdbedd1a)
- [2026 · PFE · other: Berobenatide (PF-3944) 10 Phase 3 obesity studies to start in 2026](https://app.biotechtracker.dev/events/pfe-other-2026-06-30-berobenatide-pf-3944-10-phase-3-obesity-studies-to-start-in-e91ad0d450cfdc6c)
- [2026 · PFE · other: PD-1xVEGF (PF'4404) pivotal study starts incl. 1L NSCLC](https://app.biotechtracker.dev/events/pfe-other-2026-06-30-pd-1xvegf-pf-4404-pivotal-study-starts-incl-1l-nsclc-4f1a420aab277008)
- [2026 · TAK · other: Zasocitinib regulatory submissions in plaque psoriasis (US NDA and other authorities)](https://app.biotechtracker.dev/events/tak-other-2026-06-30-zasocitinib-regulatory-submissions-in-plaque-psoriasis-us-n-82f94070d74c1b18)
- [H2 2026 · ABBV · approval: FDA decision SKYRIZI subcutaneous induction in Crohn's disease expected later in 2026](https://app.biotechtracker.dev/events/abbv-approval-2026-09-30-fda-decision-skyrizi-subcutaneous-induction-in-crohn-s-042940ef0ab908e1)
- [H2 2026 · ACAD · readout: Remlifanserin Ph2 RADIANT ADP topline narrowed to Sept–Oct 2026](https://app.biotechtracker.dev/events/acad-readout-2026-09-30-remlifanserin-ph2-radiant-adp-topline-narrowed-to-sept-o-e2499e686ae9d69e)
- [H2 2026 · ACAD · approval: European Commission decision on trofinetide (DAYBUE) in Rett syndrome](https://app.biotechtracker.dev/events/acad-approval-2026-09-30-european-commission-decision-on-trofinetide-daybue-in-r-ef877c0b02907d15)
- [H2 2026 · ACAD · readout: Trofinetide Japan Ph3 Rett syndrome topline (Oct 2026–Mar 2027 window)](https://app.biotechtracker.dev/events/acad-readout-2026-09-30-trofinetide-japan-ph3-rett-syndrome-topline-oct-2026-mar-2ee955925024fa34)
- [H2 2026 · ALNY · readout: ALN-2232 Phase 1 obesity data](https://app.biotechtracker.dev/events/alny-readout-2026-09-30-aln-2232-phase-1-obesity-data-96f2ecbaf2fb52f5)
- [H2 2026 · ALNY · readout: ALN-6400 Phase 1 (HV) and Phase 2 HHT results in 2H 2026](https://app.biotechtracker.dev/events/alny-readout-2026-09-30-aln-6400-phase-1-hv-and-phase-2-hht-results-in-2h-2026-e6ccbaafd89bbc26)
- [H2 2026 · AMGN · readout: Dazodalibep Phase 3 Sjogren's disease results](https://app.biotechtracker.dev/events/amgn-readout-2026-09-30-dazodalibep-phase-3-sjogren-s-disease-results-fa8174776da2ef27)
- [H2 2026 · AMGN · approval: EC decision on Repatha label expansion for primary prevention (VESALIUS-CV)](https://app.biotechtracker.dev/events/amgn-approval-2026-09-30-ec-decision-on-repatha-label-expansion-for-primary-prev-317ef7f23bef8fb8)
- [H2 2026 · AMGN · other: TEZSPIRE Phase 3 eosinophilic esophagitis study completion](https://app.biotechtracker.dev/events/amgn-other-2026-09-30-tezspire-phase-3-eosinophilic-esophagitis-study-completion-477cc2ab4e322e62)
- [H2 2026 · AMGN · other: UPLIZNA Phase 3 CIDP study initiation](https://app.biotechtracker.dev/events/amgn-other-2026-09-30-uplizna-phase-3-cidp-study-initiation-0674a4a33b3a2a30)
- [H2 2026 · ARWR · other: sNDA submission to FDA for plozasiran in severe hypertriglyceridemia](https://app.biotechtracker.dev/events/arwr-other-2026-09-30-snda-submission-to-fda-for-plozasiran-in-severe-hypertrigl-c0e50ec5fd5b9439)
- [H2 2026 · ARWR · readout: MUIR-3 Phase 3 topline: plozasiran in mixed hyperlipidemia](https://app.biotechtracker.dev/events/arwr-readout-2026-09-30-muir-3-phase-3-topline-plozasiran-in-mixed-hyperlipidemi-dc779a381cb8f963)
- [H2 2026 · AZN · pdufa: Extended FDA decision window for camizestrant (SERENA-6)](https://app.biotechtracker.dev/events/azn-pdufa-2026-09-30-extended-fda-decision-window-for-camizestrant-serena-6-9f4f090eb24da604)
- [H2 2026 · AZN · readout: Phase 3 AVANZAR topline: Datroway + Imfinzi in 1L NSCLC](https://app.biotechtracker.dev/events/azn-readout-2026-09-30-phase-3-avanzar-topline-datroway-imfinzi-in-1l-nsclc-9d4bb8ae52846d0d)
- [H2 2026 · BEAM · readout: Updated BEACON Phase 1/2 data for risto-cel by year-end 2026](https://app.biotechtracker.dev/events/beam-readout-2026-09-30-updated-beacon-phase-1-2-data-for-risto-cel-by-year-end-23e89fca9b0dcaa3)
- [H2 2026 · BEAM · readout: BEAM-301 initial clinical data in glycogen storage disease type Ia](https://app.biotechtracker.dev/events/beam-readout-2026-09-30-beam-301-initial-clinical-data-in-glycogen-storage-disea-a2a276aa07c8b14b)
- [H2 2026 · BIIB · conference: Litifilimab AMETHYST 52-week Phase 2 CLE data at EADV 2026](https://app.biotechtracker.dev/events/biib-conference-2026-09-30-litifilimab-amethyst-52-week-phase-2-cle-data-at-eadv-622d0695c7d2b055)
- [H2 2026 · BMY · readout: Phase 3 LIBREXIA-STROKE topline for milvexian (with J&J)](https://app.biotechtracker.dev/events/bmy-readout-2026-09-30-phase-3-librexia-stroke-topline-for-milvexian-with-j-j-3e3ec108c85007b5)
- [H2 2026 · BMY · readout: Cobenfy ADEPT-1 ADP possible interim analysis and open-label lead-in data](https://app.biotechtracker.dev/events/bmy-readout-2026-09-30-cobenfy-adept-1-adp-possible-interim-analysis-and-open-la-55cc18a8f55a4d07)
- [H2 2026 · BNTX · readout: Gotistobart (BNT316) Phase 3 interim analysis in squamous NSCLC](https://app.biotechtracker.dev/events/bntx-readout-2026-09-30-gotistobart-bnt316-phase-3-interim-analysis-in-squamous-988531b1a4a1c2c9)
- [H2 2026 · BNTX · readout: BNT113 AHEAD-MERIT Phase 3 first interim analysis in HPV16+ head and neck cancer](https://app.biotechtracker.dev/events/bntx-readout-2026-09-30-bnt113-ahead-merit-phase-3-first-interim-analysis-in-hpv-99eaca89531f7d26)
- [H2 2026 · BNTX · other: Planned BLA filing for trastuzumab pamirtecan (BNT323)](https://app.biotechtracker.dev/events/bntx-other-2026-09-30-planned-bla-filing-for-trastuzumab-pamirtecan-bnt323-a674065f0883272d)
- [H2 2026 · CRSP · readout: Zugo-cel (CTX112) updates across autoimmune disease and immuno-oncology](https://app.biotechtracker.dev/events/crsp-readout-2026-09-30-zugo-cel-ctx112-updates-across-autoimmune-disease-and-im-e6116ef2327d8734)
- [H2 2026 · CRSP · readout: CTX611 Phase 2 topline in total knee arthroplasty (VTE prevention)](https://app.biotechtracker.dev/events/crsp-readout-2026-09-30-ctx611-phase-2-topline-in-total-knee-arthroplasty-vte-pr-bedc76b8d4eb4a7c)
- [H2 2026 · CRSP · readout: CTX310 ANGPTL3 Ph1b clinical update (sHTG/refractory hypercholesterolemia)](https://app.biotechtracker.dev/events/crsp-readout-2026-09-30-ctx310-angptl3-ph1b-clinical-update-shtg-refractory-hype-ccfdfe2b30557daf)
- [H2 2026 · CYTK · other: AMBER-HFpEF Cohort 1 ulacamten enrollment completion](https://app.biotechtracker.dev/events/cytk-other-2026-09-30-amber-hfpef-cohort-1-ulacamten-enrollment-completion-dc870e30ab44fa54)
- [H2 2026 · DNLI · readout: DNL593 Phase 1/2 results in FTD-GRN](https://app.biotechtracker.dev/events/dnli-readout-2026-09-30-dnl593-phase-1-2-results-in-ftd-grn-880f3eb068cb48a9)
- [H2 2026 · EXEL · readout: STELLAR-304 Phase 3 topline in non-clear cell RCC](https://app.biotechtracker.dev/events/exel-readout-2026-09-30-stellar-304-phase-3-topline-in-non-clear-cell-rcc-44274daa8fd5f6df)
- [H2 2026 · EXEL · other: Zanzalintinib Phase 2 STELLAR-202 squamous NSCLC initiation](https://app.biotechtracker.dev/events/exel-other-2026-09-30-zanzalintinib-phase-2-stellar-202-squamous-nsclc-initiatio-1145d01d1ad0d6a3)

## Companies
- [ABBV — AbbVie Inc.](https://app.biotechtracker.dev/companies/ABBV): 3 upcoming
- [ACAD — ACADIA Pharmaceuticals Inc.](https://app.biotechtracker.dev/companies/ACAD): 3 upcoming
- [ALKS — Alkermes plc](https://app.biotechtracker.dev/companies/ALKS): 3 upcoming
- [ALNY — Alnylam Pharmaceuticals, Inc.](https://app.biotechtracker.dev/companies/ALNY): 3 upcoming
- [AMGN — Amgen Inc.](https://app.biotechtracker.dev/companies/AMGN): 6 upcoming
- [ARGX — argenx SE](https://app.biotechtracker.dev/companies/ARGX): 9 upcoming
- [ARWR — Arrowhead Pharmaceuticals, Inc.](https://app.biotechtracker.dev/companies/ARWR): 5 upcoming
- [AXSM — Axsome Therapeutics, Inc.](https://app.biotechtracker.dev/companies/AXSM): 3 upcoming
- [AZN — AstraZeneca PLC](https://app.biotechtracker.dev/companies/AZN): 5 upcoming
- [BEAM — Beam Therapeutics Inc.](https://app.biotechtracker.dev/companies/BEAM): 3 upcoming
- [BIIB — Biogen Inc.](https://app.biotechtracker.dev/companies/BIIB): 4 upcoming
- [BMRN — BioMarin Pharmaceutical Inc.](https://app.biotechtracker.dev/companies/BMRN): 4 upcoming
- [BMY — Bristol-Myers Squibb Company](https://app.biotechtracker.dev/companies/BMY): 6 upcoming
- [BNTX — BioNTech SE](https://app.biotechtracker.dev/companies/BNTX): 5 upcoming
- [CRSP — CRISPR Therapeutics AG](https://app.biotechtracker.dev/companies/CRSP): 4 upcoming
- [CYTK — Cytokinetics, Incorporated](https://app.biotechtracker.dev/companies/CYTK): 3 upcoming
- [DNLI — Denali Therapeutics Inc.](https://app.biotechtracker.dev/companies/DNLI): 7 upcoming
- [EXEL — Exelixis, Inc.](https://app.biotechtracker.dev/companies/EXEL): 3 upcoming
- [GERN — Geron Corporation](https://app.biotechtracker.dev/companies/GERN): 1 upcoming
- [GILD — Gilead Sciences, Inc.](https://app.biotechtracker.dev/companies/GILD): 8 upcoming
- [GSK — GSK plc](https://app.biotechtracker.dev/companies/GSK): 14 upcoming
- [HALO — Halozyme Therapeutics, Inc.](https://app.biotechtracker.dev/companies/HALO): 2 upcoming
- [IMVT — Immunovant, Inc.](https://app.biotechtracker.dev/companies/IMVT): 3 upcoming
- [INCY — Incyte Corporation](https://app.biotechtracker.dev/companies/INCY): 12 upcoming
- [INSM — Insmed Incorporated](https://app.biotechtracker.dev/companies/INSM): 4 upcoming
- [IONS — Ionis Pharmaceuticals, Inc.](https://app.biotechtracker.dev/companies/IONS): 3 upcoming
- [IOVA — Iovance Biotherapeutics, Inc.](https://app.biotechtracker.dev/companies/IOVA): 7 upcoming
- [JAZZ — Jazz Pharmaceuticals plc](https://app.biotechtracker.dev/companies/JAZZ): 1 upcoming
- [JNJ — Johnson & Johnson](https://app.biotechtracker.dev/companies/JNJ): 6 upcoming
- [KRYS — Krystal Biotech, Inc.](https://app.biotechtracker.dev/companies/KRYS): 11 upcoming
- [KYMR — Kymera Therapeutics, Inc.](https://app.biotechtracker.dev/companies/KYMR): 5 upcoming
- [LEGN — Legend Biotech Corporation](https://app.biotechtracker.dev/companies/LEGN): 2 upcoming
- [LLY — Eli Lilly and Company](https://app.biotechtracker.dev/companies/LLY): 2 upcoming
- [MDGL — Madrigal Pharmaceuticals, Inc.](https://app.biotechtracker.dev/companies/MDGL): 2 upcoming
- [MRK — Merck & Co., Inc.](https://app.biotechtracker.dev/companies/MRK): 1 upcoming
- [MRNA — Moderna, Inc.](https://app.biotechtracker.dev/companies/MRNA): 2 upcoming
- [NBIX — Neurocrine Biosciences, Inc.](https://app.biotechtracker.dev/companies/NBIX): 2 upcoming
- [NTLA — Intellia Therapeutics, Inc.](https://app.biotechtracker.dev/companies/NTLA): 3 upcoming
- [NVAX — Novavax, Inc.](https://app.biotechtracker.dev/companies/NVAX): 2 upcoming
- [NVO — Novo Nordisk A/S](https://app.biotechtracker.dev/companies/NVO): 9 upcoming
- [NVS — Novartis AG](https://app.biotechtracker.dev/companies/NVS): 19 upcoming
- [PCVX — Vaxcyte, Inc.](https://app.biotechtracker.dev/companies/PCVX): 3 upcoming
- [PFE — Pfizer Inc.](https://app.biotechtracker.dev/companies/PFE): 6 upcoming
- [PTCT — PTC Therapeutics, Inc.](https://app.biotechtracker.dev/companies/PTCT): 2 upcoming
- [RARE — Ultragenyx Pharmaceutical Inc.](https://app.biotechtracker.dev/companies/RARE): 5 upcoming
- [REGN — Regeneron Pharmaceuticals, Inc.](https://app.biotechtracker.dev/companies/REGN): 2 upcoming
- [RXRX — Recursion Pharmaceuticals, Inc.](https://app.biotechtracker.dev/companies/RXRX): 7 upcoming
- [RYTM — Rhythm Pharmaceuticals, Inc.](https://app.biotechtracker.dev/companies/RYTM): 4 upcoming
- [SMMT — Summit Therapeutics Inc.](https://app.biotechtracker.dev/companies/SMMT): 3 upcoming
- [SNY — Sanofi](https://app.biotechtracker.dev/companies/SNY): 16 upcoming
- [SRPT — Sarepta Therapeutics, Inc.](https://app.biotechtracker.dev/companies/SRPT): 4 upcoming
- [TAK — Takeda Pharmaceutical Company Limited](https://app.biotechtracker.dev/companies/TAK): 3 upcoming
- [TGTX — TG Therapeutics, Inc.](https://app.biotechtracker.dev/companies/TGTX): 3 upcoming
- [UTHR — United Therapeutics Corporation](https://app.biotechtracker.dev/companies/UTHR): 5 upcoming
- [VKTX — Viking Therapeutics, Inc.](https://app.biotechtracker.dev/companies/VKTX): 2 upcoming
- [VRTX — Vertex Pharmaceuticals Incorporated](https://app.biotechtracker.dev/companies/VRTX): 8 upcoming

## Optional
- [About](https://app.biotechtracker.dev/about)
- [Terms](https://app.biotechtracker.dev/terms)
- [Privacy](https://app.biotechtracker.dev/privacy)
- [Disclaimer](https://app.biotechtracker.dev/disclaimer)